TY - JOUR T1 - Outcomes of SARS-CoV-2 Infection in Patients with Chronic Liver Disease and Cirrhosis: a N3C Study JF - medRxiv DO - 10.1101/2021.06.03.21258312 SP - 2021.06.03.21258312 AU - Jin Ge AU - Mark J. Pletcher AU - Jennifer C. Lai AU - for the N3C Consortium Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/07/2021.06.03.21258312.abstract N2 - Background and Aims In patients with chronic liver diseases (CLD) with or without cirrhosis, existing data on the risk of adverse outcomes with SARS-CoV-2 infection have been mixed or have limited generalizability. We used the National COVID Cohort Collaborative (N3C) Data Enclave, a harmonized electronic health record (EHR) dataset of 5.9 million nationally-representative, diverse, and gender-balanced patients, to describe outcomes in patients with CLD and cirrhosis with SARS-CoV-2.Methods We identified all chronic liver diseases patients with and without cirrhosis who had SARS-CoV-2 testing documented in the N3C Data Enclave as of data release date 5/15/2021. The primary outcome was 30-day all-cause mortality. Survival analysis methods were used to estimate cumulative incidences of death, hospitalization, and mechanical ventilation, and to calculate the associations of SARS-CoV-2 infection, presence of cirrhosis, and demographic and clinical factors to 30-day mortality.Results We isolated 217,143 patients with CLD: 129,097 (59%) without cirrhosis and SARS-CoV-2 negative, 25,844 (12%) without cirrhosis and SARS-CoV-2 positive, 54,065 (25%) with cirrhosis and SARS-CoV-2 negative, and 8,137 (4%) with cirrhosis and SARS-CoV-2 positive. Among CLD patients without cirrhosis, 30-day all-cause mortality rates were 0.4% in SARS-CoV-2 negative patients and 1.8% in positive patients. Among CLD patients with cirrhosis, 30-day all-cause mortality rates were 4.0% in SARS-CoV-2 negative patients and 9.7% in positive patients.Compared to those who tested SARS-CoV-2 negative, SARS-CoV-2 positivity was associated with more than two-fold (aHR 2.43, 95% CI 2.23-2.64) hazard of death at 30 days among patients with cirrhosis. Compared to patients without cirrhosis, the presence of cirrhosis was associated with a three-fold (aHR 3.39, 95% CI 2.96-3.89) hazard of death at 30 days among patients who tested SARS-CoV-2 positive. Age (aHR 1.03 per year, 95% CI 1.03-1.04) was associated with death at 30 days among patients with cirrhosis who were SARS-CoV-2 positive.Conclusions In this study of nearly 220,000 CLD patients, we found SARS-CoV-2 infection in patients with cirrhosis was associated with 2.43-times mortality hazard, and the presence of cirrhosis among CLD patients infected with SARS-CoV-2 were associated with 3.39-times mortality hazard. Compared to previous studies, our use of a nationally-representative, diverse, and gender-balanced dataset enables wide generalizability of these findings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFinancial Support The authors of this study were supported by 5T32DK060414-18 (National Institute of Diabetes and Digestive and Kidney Diseases, Ge), UL1TR001872 (National Center for Advancing Translational Sciences, Pletcher), R01AG059183 (National Institute on Aging, Lai), and P30DK026743 (UCSF Liver Center Grant, Lai). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or any other funding agencies. The funding agencies played no role in the analysis of the data or the preparation of this manuscript. Acknowledgements: The analyses described in this publication were conducted with data or tools accessed through the NCATS N3C Data Enclave covid.cd2h.org/enclave and supported by NCATS U24 TR002306. This research was possible because of the patients whose information is included within the data from participating organizations (covid.cd2h.org/dtas) and the organizations and scientists (covid.cd2h.org/duas) who have contributed to the on-going development of this community resource (cite this https://doi.org/10.1093/jamia/ocaa196). The N3C data transfer to NCATS is performed under a Johns Hopkins University Reliance Protocol # IRB00249128 or individual site agreements with NIH. The N3C Data Enclave is managed under the authority of the NIH; information can be found at https://ncats.nih.gov/n3c/resources. We gratefully acknowledge contributions from the following N3C core teams: -Principal Investigators: Melissa A. Haendel*, Christopher G. Chute*, Kenneth R. Gersing, Anita Walden - Workstream, subgroup and administrative leaders: Melissa A. Haendel*, Tellen D. Bennett, Christopher G. Chute, David A. Eichmann, Justin Guinney, Warren A. Kibbe, Hongfang Liu, Philip R.O. Payne, Emily R. Pfaff, Peter N. Robinson, Joel H. Saltz, Heidi Spratt, Justin Starren, Christine Suver, Adam B. Wilcox, Andrew E. Williams, Chunlei Wu -Key liaisons at data partner sites -Regulatory staff at data partner sites -Individuals at the sites who are responsible for creating the datasets and submitting data to N3C -Data Ingest and Harmonization Team: Christopher G. Chute*, Emily R. Pfaff*, Davera Gabriel, Stephanie S. Hong, Kristin Kostka, Harold P. Lehmann, Richard A. Moffitt, Michele Morris, Matvey B. Palchuk, Xiaohan Tanner Zhang, Richard L. Zhu -Phenotype Team (Individuals who create the scripts that the sites use to submit their data, based on the COVID and Long COVID definitions): Emily R. Pfaff*, Benjamin Amor, Mark M. Bissell, Marshall Clark, Andrew T. Girvin, Stephanie S. Hong, Kristin Kostka, Adam M. Lee, Robert T. Miller, Michele Morris, Matvey B. Palchuk, Kellie M. Walters -Project Management and Operations Team: Anita Walden*, Yooree Chae, Connor Cook, Alexandra Dest, Racquel R. Dietz, Thomas Dillon, Patricia A. Francis, Rafael Fuentes, Alexis Graves, Andrew J. Neumann, Shawn T. O'Neil, Andrea M. Volz, Elizabeth Zampino -Partners from NIH and other federal agencies: Christopher P. Austin*, Kenneth R. Gersing*, Samuel Bozzette, Mariam Deacy, Nicole Garbarini, Michael G. Kurilla, Sam G. Michael, Joni L. Rutter, Meredith Temple-O'Connor -Analytics Team (Individuals who build the Enclave infrastructure, help create codesets, variables, and help Domain Teams and project teams with their datasets): Benjamin Amor*, Mark M. Bissell, Katie Rebecca Bradwell, Andrew T. Girvin, Amin Manna, Nabeel Qureshi The authors thank the Publication Committee for their review of this publication to ensure compliance with ICMJE guidelines, the N3C User Code of Conduct, and appropriate author attribution. -Publication Committee Review Team: Carolyn Bramante, Jeremy R. Harper, Wendy Hernandez, Farrukh M. Koraishy, Saidulu Mattapally, Amit Saha, Satyanarayana Vedula Stony Brook University - U24TR002306, University of Oklahoma Health Sciences Center - U54GM104938: Oklahoma Clinical and Translational Science Institute (OCTSI), West Virginia University - U54GM104942: West Virginia Clinical and Translational Science Institute (WVCTSI), University of Mississippi Medical Center - U54GM115428: Mississippi Center for Clinical and Translational Research (CCTR), University of Nebraska Medical Center - U54GM115458: Great Plains IDeA-Clinical & Translational Research, Maine Medical Center - U54GM115516: Northern New England Clinical & Translational Research (NNE-CTR) Network, Wake Forest University Health Sciences - UL1TR001420: Wake Forest Clinical and Translational Science Institute, Northwestern University at Chicago - UL1TR001422: Northwestern University Clinical and Translational Science Institute (NUCATS), University of Cincinnati - UL1TR001425: Center for Clinical and Translational Science and Training, The University of Texas Medical Branch at Galveston - UL1TR001439: The Institute for Translational Sciences, Medical University of South Carolina - UL1TR001450: South Carolina Clinical & Translational Research Institute (SCTR), University of Massachusetts Medical School Worcester - UL1TR001453: The UMass Center for Clinical and Translational Science (UMCCTS), University of Southern California - UL1TR001855: The Southern California Clinical and Translational Science Institute (SC CTSI), Columbia University Irving Medical Center - UL1TR001873: Irving Institute for Clinical and Translational Research, George Washington Children's Research Institute - UL1TR001876: Clinical and Translational Science Institute at Children's National (CTSA-CN), University of Kentucky - UL1TR001998: UK Center for Clinical and Translational Science, University of Rochester - UL1TR002001: UR Clinical & Translational Science Institute, University of Illinois at Chicago - UL1TR002003: UIC Center for Clinical and Translational Science, Penn State Health Milton S. Hershey Medical Center - UL1TR002014: Penn State Clinical and Translational Science Institute, The University of Michigan at Ann Arbor - UL1TR002240: Michigan Institute for Clinical and Health Research, Vanderbilt University Medical Center - UL1TR002243: Vanderbilt Institute for Clinical and Translational Research, University of Washington - UL1TR002319: Institute of Translational Health Sciences, Washington University in St. Louis - UL1TR002345: Institute of Clinical and Translational Sciences, Oregon Health & Science University - UL1TR002369: Oregon Clinical and Translational Research Institute, University of Wisconsin-Madison - UL1TR002373: UW Institute for Clinical and Translational Research, Rush University Medical Center - UL1TR002389: The Institute for Translational Medicine (ITM), The University of Chicago - UL1TR002389: The Institute for Translational Medicine (ITM), University of North Carolina at Chapel Hill - UL1TR002489: North Carolina Translational and Clinical Science Institute, University of Minnesota - UL1TR002494: Clinical and Translational Science Institute, Children's Hospital Colorado - UL1TR002535: Colorado Clinical and Translational Sciences Institute, The University of Iowa - UL1TR002537: Institute for Clinical and Translational Science, The University of Utah - UL1TR002538: Uhealth Center for Clinical and Translational Science, Tufts Medical Center - UL1TR002544: Tufts Clinical and Translational Science Institute, Duke University - UL1TR002553: Duke Clinical and Translational Science Institute, Virginia Commonwealth University - UL1TR002649: C. Kenneth and Dianne Wright Center for Clinical and Translational Research, The Ohio State University - UL1TR002733: Center for Clinical and Translational Science, The University of Miami Leonard M. Miller School of Medicine - UL1TR002736: University of Miami Clinical and Translational Science Institute, University of Virginia - UL1TR003015: iTHRIVL Integrated Translational health Research Institute of Virginia, Carilion Clinic - UL1TR003015: iTHRIVL Integrated Translational health Research Institute of Virginia, University of Alabama at Birmingham - UL1TR003096: Center for Clinical and Translational Science, Johns Hopkins University - UL1TR003098: Johns Hopkins Institute for Clinical and Translational Research, University of Arkansas for Medical Sciences - UL1TR003107: UAMS Translational Research Institute, Nemours - U54GM104941: Delaware CTR ACCEL Program, University Medical Center New Orleans - U54GM104940: Louisiana Clinical and Translational Science (LA CaTS) Center, University of Colorado Denver, Anschutz Medical Campus - UL1TR002535: Colorado Clinical and Translational Sciences Institute, Mayo Clinic Rochester - UL1TR002377: Mayo Clinic Center for Clinical and Translational Science (CCaTS), Tulane University - UL1TR003096: Center for Clinical and Translational Science, Loyola University Medical Center - UL1TR002389: The Institute for Translational Medicine (ITM), Advocate Health Care Network - UL1TR002389: The Institute for Translational Medicine (ITM), OCHIN - INV-018455: Bill and Melinda Gates Foundation grant to Sage Bionetworks, The Rockefeller University - UL1TR001866: Center for Clinical and Translational Science, The Scripps Research Institute - UL1TR002550: Scripps Research Translational Institute, University of Texas Health Science Center at San Antonio - UL1TR002645: Institute for Integration of Medicine and Science, The University of Texas Health Science Center at Houston - UL1TR003167: Center for Clinical and Translational Sciences (CCTS), NorthShore University HealthSystem - UL1TR002389: The Institute for Translational Medicine (ITM), Yale New Haven Hospital - UL1TR001863: Yale Center for Clinical Investigation, Emory University - UL1TR002378: Georgia Clinical and Translational Science Alliance, Weill Medical College of Cornell University - UL1TR002384: Weill Cornell Medicine Clinical and Translational Science Center, Montefiore Medical Center - UL1TR002556: Institute for Clinical and Translational Research at Einstein and Montefiore, Medical College of Wisconsin - UL1TR001436: Clinical and Translational Science Institute of Southeast Wisconsin, University of New Mexico Health Sciences Center - UL1TR001449: University of New Mexico Clinical and Translational Science Center, George Washington University - UL1TR001876: Clinical and Translational Science Institute at Children's National (CTSA-CN), Stanford University - UL1TR003142: Spectrum: The Stanford Center for Clinical and Translational Research and Education, Regenstrief Institute - UL1TR002529: Indiana Clinical and Translational Science Institute, Cincinnati Children's Hospital Medical Center - UL1TR001425: Center for Clinical and Translational Science and Training, Boston University Medical Campus - UL1TR001430: Boston University Clinical and Translational Science Institute, The State University of New York at Buffalo - UL1TR001412: Clinical and Translational Science Institute, Aurora Health Care - UL1TR002373: Wisconsin Network For Health Research, Brown University - U54GM115677: Advance Clinical Translational Research (Advance-CTR), Rutgers, The State University of New Jersey - UL1TR003017: New Jersey Alliance for Clinical and Translational Science, Loyola University Chicago - UL1TR002389: The Institute for Translational Medicine (ITM), #N/A - UL1TR001445: Langone Health's Clinical and Translational Science Institute, Children's Hospital of Philadelphia - UL1TR001878: Institute for Translational Medicine and Therapeutics, University of Kansas Medical Center - UL1TR002366: Frontiers: University of Kansas Clinical and Translational Science Institute, Massachusetts General Brigham - UL1TR002541: Harvard Catalyst, Icahn School of Medicine at Mount Sinai - UL1TR001433: ConduITS Institute for Translational Sciences, Ochsner Medical Center - U54GM104940: Louisiana Clinical and Translational Science (LA CaTS) Center, HonorHealth - None (Voluntary), University of California, Irvine - UL1TR001414: The UC Irvine Institute for Clinical and Translational Science (ICTS), University of California, San Diego - UL1TR001442: Altman Clinical and Translational Research Institute, University of California, Davis - UL1TR001860: UCDavis Health Clinical and Translational Science Center, University of California, San Francisco - UL1TR001872: UCSF Clinical and Translational Science Institute, University of California, Los Angeles - UL1TR001881: UCLA Clinical Translational Science Institute, University of Vermont - U54GM115516: Northern New England Clinical & Translational Research (NNE-CTR) Network, Arkansas Children's Hospital - UL1TR003107: UAMS Translational Research InstituteAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board Oversight Submission of data from individual centers to N3C are governed by a central institutional review board (IRB) protocol #IRB00249128 hosted at Johns Hopkins University School of Medicine via the SMART IRB40 Master Common Reciprocal reliance agreement. This central IRB cover data contributions and transfer to N3C and does not cover research using N3C data. If elected, individual sites may choose to exercise their own local IRB agreements instead of utilizing the central IRB. As NCATs is the steward of the repository, data received and hosted by NCATs on the N3C Data Enclave, its maintenance, and its storage are covered under a central NIH IRB protocol to make EHR-derived data available for the clinical and research community to use for studying COVID-19. Our institution has an active data transfer agreement with N3C. This specific analysis of the N3C Enclave was approved by N3C under the Data Use Agreement titled "[RP-7C5E62] COVID-19 Outcomes in Patients with Cirrhosis." The use of N3C data for this study was authorized by the IRB at the University of California, San Francisco under #20-33149.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe N3C Data Enclave (covid.cd2h.org/enclave) houses fully reproducible, transparent, and broadly available limited and de-identified datasets (HIPAA definitions: https://www.hhs.gov/hipaa/for-professionals/privacy/specialtopics/de-identification/index.html). Data is accessible by investigators at institutions that have signed a Data Use Agreement with NIH who have taken human subjects and security training and attest to the N3C User Code of Conduct. Investigators wishing to access the limited dataset must also supply an institutional IRB protocol. All requests for data access are reviewed by the NIH Data Access Committee. A full description of the N3C Enclave governance has been published;193 information about how to apply for access is available on the NCATS website: https://ncats.nih.gov/n3c/about/applying-for-access. Reviewers and health authorities will be given access permission and guidance to aid reproducibility and outcomes assessment. A Frequently Asked Questions about the data and access has been created at: https://ncats.nih.gov/n3c/about/program-faq The data model is OMOP 5.3.1, specifications are posted at: https://ncats.nih.gov/files/OMOP_CDM_COVID.pdfAALDalcohol-associated liver diseaseaHRadjusted hazard ratioASTaspartate transaminaseALTalanine transaminaseBMIbody mass indexCCICharlson Comorbidity IndexCD2HCenter for Data to HealthCDCCenters for Disease Control and PreventionCLDchronic liver diseaseCTSAClinical and Translational Science AwardsEHRelectronic health recordICD-10-CMInternational Classification of Diseases, Tenth Revision, Clinical ModificationHRhazard ratioINRinternational normalized ratioIQRinterquartile rangeIRBinstitutional review boardMELD-NaModel for End-Stage Liver Disease-SodiumN3CNational COVID Cohort CollaborativeNAFLDnon-alcoholic fatty liver diseaseNCATSNational Center for Advancing Translational SciencesNIHNational Institutes of HealthNREVSSNational Respiratory and Enteric Virus Surveillance SystemOHDSIObservational Health Data Sciences and Informatics NetworkOMOPObservational Medical Outcomes PartnershipSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2SNOMEDStandard Nomenclature of Medicine ER -